CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg/m²) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg/m²) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06573645
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:14.914966+00:00
Published At: 2024-08-27T00:00:00+00:00
Record Updated At: 2024-08-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, Large B-Cell, Diffuse"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-27"
protocolSection.identificationModule.nctId: "NCT06573645"
protocolSection.identificationModule.officialTitle: "A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg/m\u00b2) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg/m\u00b2) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.